Multiple Myeloma Patients Undergoing Carfilzomib: Development and Validation of a Risk Score for Cardiovascular Adverse Events Prediction

SIMPLE SUMMARY: Despite the relationship between Carfilzomib (CFZ) therapy in multiple myeloma (MM) and cardiovascular adverse events (CVAEs), no specific validated protocols on cardiovascular risk assessment are available. In this prospective study, we investigated major predictors of CVAEs prior t...

Descripción completa

Detalles Bibliográficos
Autores principales: Astarita, Anna, Mingrone, Giulia, Airale, Lorenzo, Vallelonga, Fabrizio, Covella, Michele, Catarinella, Cinzia, Cesareo, Marco, Bruno, Giulia, Leone, Dario, Giordana, Carlo, Cetani, Giusy, Salvini, Marco, Gay, Francesca, Bringhen, Sara, Rabbia, Franco, Veglio, Franco, Milan, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036868/
https://www.ncbi.nlm.nih.gov/pubmed/33915804
http://dx.doi.org/10.3390/cancers13071631

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036868/
https://www.ncbi.nlm.nih.gov/pubmed/33915804
http://dx.doi.org/10.3390/cancers13071631

Ejemplares similares